

## PRESS RELEASE

March 8, 2019

Nanologica to attend BIO-Europe Spring 2019 in Vienna for partnering discussions  
**Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25 – 27 to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™.**

Nanologica strives to be the world leader in nanoporous silica particles in its two business areas: Drug Delivery and Chromatography. Nanologica has developed a drug delivery platform based on its nanoporous silica particles, NLAB Silica™, for improved delivery and absorption of active pharmaceutical ingredients.

By loading the API in NLAB Silica™ particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the benefits of using NLAB Silica™ includes stabilization and protection of the API, controlled release and increased solubility of the API.

Nanologica is currently involved in several clinical trials, with its own asset, NIC-001, which is a drug candidate in phase II for the treatment of gastroparesis, as well as in collaboration projects with large and mid-size pharma. On January 30, 2019, Nanologica and AstraZeneca entered into an agreement for the evaluation of Nanologica’s technology applied to AstraZeneca materials. On May 16, 2018 Nanologica licensed parts of its technology platform to Vicore Pharma AB for use in several of their upcoming clinical trials.

Nanologica is interested in partnering with pharma companies within the gastrointestinal area and is also seeking partnership for further drug delivery applications using NLAB Silica™.

To schedule a meeting, please do so via BIO-Europe’s online partnering platform at: [www.partneringone.com](http://www.partneringone.com), or contact:

Kia Bengtsson, Director Clinical Development, Nanologica AB  
phone: +46 70 144 36 30 or e-mail [kia.bengtsson@nanologica.com](mailto:kia.bengtsson@nanologica.com)

For technical information on Nanologica’s drug delivery platform, please contact:

Prof. Adam Feiler, CTO Nanologica AB  
phone: +46 72 353 66 30 or e-mail [adam.feiler@nanologica.com](mailto:adam.feiler@nanologica.com)

**For further information, please contact:**

Andreas Bhagwani, CEO Nanologica AB  
phone: +46 70 316 17 02 or e-mail: [andreas.bhagwani@nanologica.com](mailto:andreas.bhagwani@nanologica.com)

**About Nanologica**

Nanologica AB (publ) develops nanoporous silica for applications in life science. The company focuses on two business areas: drug delivery and chromatography, a technology used for the separation and purification of products on the market and in development. Nanologica’s core competency is to apply its unique know-how in the field of material science for developing nanoporous silica particles with unique characteristics. The company’s stock is traded on Spotlight Stock Market (ticker NICA). For more information, please visit [www.nanologica.com](http://www.nanologica.com).